Reactivation of dormant anti-tumor immunity – a clinical perspective of therapeutic immune checkpoint modulation

[1]  Uma Yasothan,et al.  Brentuximab vedotin , 2022, Nature Reviews Drug Discovery.

[2]  P. Timpson.  Faculty Opinions recommendation of The topography of mutational processes in breast cancer genomes. , 2018, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[3]  M. Shipp,et al.  Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Blaser,et al.  The Intestinal Microbiome and Estrogen Receptor-Positive Female Breast Cancer. , 2016, Journal of the National Cancer Institute.

[5]  K. Harrington,et al.  Abstract CT099: Nivolumab (nivo) vs investigator's choice (IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141 , 2016 .

[6]  M. L. Calle,et al.  Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. , 2016, Cancer cell.

[7]  HaroldC. Smith,et al.  The APOBEC Protein Family: United by Structure, Divergent in Function. , 2016, Trends in biochemical sciences.

[8]  L. Pleyer,et al.  Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis—Masters of Survival and Clonality? , 2016, International journal of molecular sciences.

[9]  G. Freeman,et al.  Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma , 2016, Scientific Reports.

[10]  Nicola D. Roberts,et al.  Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.

[11]  James X. Sun,et al.  Tumor mutational burden as a potential biomarker for PD1/PD-L1 therapy in colorectal cancer. , 2016 .

[12]  J. Desai,et al.  Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). , 2016 .

[13]  S. Mortimer,et al.  Somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA. , 2016 .

[14]  R. Dummer,et al.  The peripheral blood TCR repertoire to facilitate patient stratification for immune checkpoint blockade inhibition in metastatic melanoma. , 2016 .

[15]  R. Bourgon,et al.  PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210). , 2016 .

[16]  R. Bourgon,et al.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.

[17]  J. Taube,et al.  Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy , 2016, Nature Reviews Cancer.

[18]  A. Jakubowiak,et al.  Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial , 2016, The Lancet.

[19]  Haiyi Jiang,et al.  Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti‐programmed cell death‐ligand‐1 (PD‐L1) antibody, combined with gefitinib (G): A phase I expansion in TKI‐naïve patients (pts) with EGFR mutant NSCLC: 57O , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  A. Sieuwerts,et al.  APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma , 2016, Clinical Cancer Research.

[21]  A. Taddei,et al.  The interplay between the microbiome and the adaptive immune response in cancer development , 2016, Therapeutic advances in gastroenterology.

[22]  C. Flowers,et al.  Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies. , 2016, Clinical colorectal cancer.

[23]  Yan Cai,et al.  Ovarian carcinoma-infiltrating regulatory T cells were more potent suppressors of CD8+ T cell inflammation than their peripheral counterparts, a function dependent on TIM3 expression , 2016, Tumor Biology.

[24]  M. Guerreiro,et al.  Trastuzumab in the Treatment of Breast Cancer , 2016, BioDrugs.

[25]  Shohei Koyama,et al.  Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints , 2016, Nature Communications.

[26]  Amanda R. Campbell,et al.  Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment. , 2016, Cancer research.

[27]  R. Weissleder,et al.  Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. , 2016, Immunity.

[28]  G. Lesinski,et al.  Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer , 2015, Clinical Cancer Research.

[29]  T. Kipps,et al.  Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. , 2015, The New England journal of medicine.

[30]  L. Zitvogel,et al.  Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. , 2015, Cancer cell.

[31]  J. Gartner,et al.  Immunogenicity of somatic mutations in human gastrointestinal cancers , 2015, Science.

[32]  F. Ginhoux,et al.  Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota , 2015, Science.

[33]  J. Gartner,et al.  Selection of circulating PD-1+ lymphocytes from cancer patients enriches for tumor-reactive and mutation-specific lymphocytes , 2015, Journal of Immunotherapy for Cancer.

[34]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[35]  I. Márquez-Rodas,et al.  Immune checkpoint inhibitors: therapeutic advances in melanoma. , 2015, Annals of translational medicine.

[36]  Preet Paul Singh,et al.  Immune checkpoints and immunotherapy for colorectal cancer , 2015, Gastroenterology report.

[37]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[38]  M. Valsecchi.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[39]  Gad Getz,et al.  An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers , 2015, Nature Genetics.

[40]  E. Wherry,et al.  Molecular and cellular insights into T cell exhaustion , 2015, Nature Reviews Immunology.

[41]  I. Melero,et al.  Evolving synergistic combinations of targeted immunotherapies to combat cancer , 2015, Nature Reviews Cancer.

[42]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[43]  Carsten Denkert,et al.  Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. , 2015, JAMA oncology.

[44]  C. Swanton,et al.  APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity. , 2015, Cancer discovery.

[45]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[46]  B. Vogelstein,et al.  PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Jedd D. Wolchok,et al.  Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma , 2015, Journal of Immunotherapy for Cancer.

[48]  A. Ng,et al.  A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab , 2015, Oncoimmunology.

[49]  A. Eggermont,et al.  Correction to Lancet Oncol 2015; 16: 522-30. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. , 2015, The Lancet. Oncology.

[50]  G. Linette,et al.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.

[51]  P. Stephens,et al.  Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies. , 2015, The oncologist.

[52]  P. Ascierto,et al.  Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. , 2015, The Lancet. Oncology.

[53]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[54]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[55]  G. Linette,et al.  Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. , 2015, The Lancet. Oncology.

[56]  Carsten Denkert,et al.  Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  H. Kohrt,et al.  Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK , 2015, Proceedings of the National Academy of Sciences.

[58]  Benjamin Haibe-Kains,et al.  APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation , 2015, Proceedings of the National Academy of Sciences.

[59]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[60]  M. Vetizou,et al.  Cancer and the gut microbiota: An unexpected link , 2015, Science Translational Medicine.

[61]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[62]  Gordon Cook,et al.  APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma , 2014, Nature Communications.

[63]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[64]  C. Craddock,et al.  Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia , 2014, Annals of Hematology.

[65]  K. Kinzler,et al.  Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells , 2014, Journal of Immunotherapy for Cancer.

[66]  J. Byrd,et al.  Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. , 2014, The New England journal of medicine.

[67]  S. Henderson,et al.  APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. , 2014, Cell reports.

[68]  B. Isermann,et al.  Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function , 2014, Haematologica.

[69]  G. Trinchieri,et al.  Gut microbiome and anticancer immune response: really hot Sh*t! , 2014, Cell Death and Differentiation.

[70]  R. Greil,et al.  APOBEC3 signature mutations in chronic lymphocytic leukemia , 2014, Leukemia.

[71]  Antoni Ribas,et al.  Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma , 2014, Clinical Cancer Research.

[72]  R. Greil,et al.  Alternative splice variants of AID are not stoichiometrically present at the protein level in chronic lymphocytic leukemia , 2014, European journal of immunology.

[73]  Ryan Emerson,et al.  CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire , 2014, Clinical Cancer Research.

[74]  Chris P. Miller,et al.  JAK2 Expression Is Associated with Tumor-Infiltrating Lymphocytes and Improved Breast Cancer Outcomes: Implications for Evaluating JAK2 Inhibitors , 2014, Cancer Immunology Research.

[75]  Sung-Liang Yu,et al.  Sorafenib relieves cell‐intrinsic and cell‐extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity , 2014, International journal of cancer.

[76]  F. Marincola,et al.  Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment , 2013, Science.

[77]  Eric Vivier,et al.  The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide , 2013, Science.

[78]  A. Rudensky,et al.  Metabolites produced by commensal bacteria promote peripheral regulatory T cell generation , 2013, Nature.

[79]  J. Wolchok,et al.  Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor , 2013, Cancer Immunology Research.

[80]  Jeffrey A Jones,et al.  Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. , 2013, Blood.

[81]  N. A. Temiz,et al.  Evidence for APOBEC3B mutagenesis in multiple human cancers , 2013, Nature Genetics.

[82]  Steven A. Roberts,et al.  An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers , 2013, Nature Genetics.

[83]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[84]  M. Nussenzweig,et al.  Chromosome translocation, B cell lymphoma, and activation-induced cytidine deaminase. , 2013, Annual review of pathology.

[85]  S. Fagarasan,et al.  Impaired selection of IgA and intestinal dysbiosis associated with PD-1-deficiency , 2013, Gut microbes.

[86]  J. Baselga,et al.  Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.

[87]  H. Tjalsma,et al.  Gut bacteria in health and disease: a survey on the interface between intestinal microbiology and colorectal cancer , 2012, Biological reviews of the Cambridge Philosophical Society.

[88]  J. Moorman,et al.  Tim-3 Pathway Controls Regulatory and Effector T Cell Balance during Hepatitis C Virus Infection , 2012, The Journal of Immunology.

[89]  Bas E Dutilh,et al.  A bacterial driver–passenger model for colorectal cancer: beyond the usual suspects , 2012, Nature Reviews Microbiology.

[90]  S. Tannenbaum,et al.  Infection-induced colitis in mice causes dynamic and tissue-specific changes in stress response and DNA damage leading to colon cancer , 2012, Proceedings of the National Academy of Sciences.

[91]  D. Maloney.  Anti-CD20 antibody therapy for B-cell lymphomas. , 2012, The New England journal of medicine.

[92]  Jedd D. Wolchok,et al.  Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.

[93]  Peter Vogel,et al.  Microenvironment and Immunology Immune Inhibitory Molecules Lag-3 and Pd-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape , 2022 .

[94]  U. Gophna.  The Guts of Dietary Habits , 2011, Science.

[95]  J. Gordon,et al.  Human nutrition, the gut microbiome and the immune system , 2011, Nature.

[96]  F. Ghiringhelli,et al.  Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer , 2011, Cancer Immunology, Immunotherapy.

[97]  E John Wherry,et al.  T cell exhaustion , 2011 .

[98]  P. Bork,et al.  Enterotypes of the human gut microbiome , 2011, Nature.

[99]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[100]  Jenna M. Sullivan,et al.  Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity , 2010, The Journal of experimental medicine.

[101]  J. Kirkwood,et al.  Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients , 2010, The Journal of experimental medicine.

[102]  M. Kadin,et al.  Targeted therapies: Denileukin diftitox—a step towards a 'magic bullet' for CTCL , 2010, Nature Reviews Clinical Oncology.

[103]  R. Lorenz,et al.  Role of Postnatal Acquisition of the Intestinal Microbiome in the Early Development of Immune Function , 2010, Journal of pediatric gastroenterology and nutrition.

[104]  Loise M. Francisco,et al.  The PD‐1 pathway in tolerance and autoimmunity , 2010, Immunological reviews.

[105]  Cynthia L Sears,et al.  A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses , 2009, Nature Medicine.

[106]  S. Mazmanian,et al.  The gut microbiota shapes intestinal immune responses during health and disease , 2009, Nature Reviews Immunology.

[107]  M. Croft.  The role of TNF superfamily members in T-cell function and diseases , 2009, Nature Reviews Immunology.

[108]  M. Ligtenberg,et al.  Deficient mismatch repair system in patients with sporadic advanced colorectal cancer , 2009, British Journal of Cancer.

[109]  A. Stringer,et al.  Faecal microflora and β-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats , 2008, Cancer biology & therapy.

[110]  L. Zitvogel,et al.  The anticancer immune response: indispensable for therapeutic success? , 2008, The Journal of clinical investigation.

[111]  A. Sharpe,et al.  Induction of autoimmune disease in CTLA-4−/− mice depends on a specific CD28 motif that is required for in vivo costimulation , 2007, Proceedings of the National Academy of Sciences.

[112]  Carmen Buchrieser,et al.  Escherichia coli Induces DNA Double-Strand Breaks in Eukaryotic Cells , 2006, Science.

[113]  J. Nicoli,et al.  Germ-free mice produce high levels of interferon-gamma in response to infection with Leishmania major but fail to heal lesions , 2005, Parasitology.

[114]  J. Nicoli,et al.  Influence of normal microbiota on some aspects of the immune response during experimental infection with Trypanosoma cruzi in mice. , 2004, Journal of medical microbiology.

[115]  R. Greil,et al.  Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools , 2003, Journal of leukocyte biology.

[116]  T. Honjo,et al.  Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. , 1999, Immunity.

[117]  R. Fisher,et al.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[118]  D. C. Cara,et al.  Monoassociation with Lactobacillus acidophilus UFV-H2b20 stimulates the immune defense mechanisms of germfree mice. , 1998, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[119]  R. Greil,et al.  Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia. , 1998, Blood.

[120]  R. Greil,et al.  Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. , 1997, Cancer research.

[121]  R. Greil,et al.  Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. , 1997, Blood.

[122]  M Nomura,et al.  Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. , 1996, Cancer research.

[123]  A. Nagler,et al.  Role of interleukin-2 in human hematological malignancies , 1995, Medical oncology.

[124]  M. Ratain,et al.  Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. , 1994, Cancer research.

[125]  J. Cawley,et al.  The current status of interferonα in haemic malignancy , 1990 .

[126]  W. Coley,et al.  Contribution To The Knowledge Of Sarcoma , 1891 .

[127]  E. Levanon,et al.  DNA Editing by APOBECs: A Genomic Preserver and Transformer. , 2016, Trends in genetics : TIG.

[128]  ADC Shows Effectiveness in SCLC. , 2015, Cancer discovery.

[129]  S. Mazmanian,et al.  The gut microbiome shapes intestinal immune responses during health and disease , 2014 .

[130]  R. Greil,et al.  Tuning the rheostat of the myelopoietic system via Fas and TRAIL. , 2003, Critical reviews in immunology.

[131]  A. Eggermont,et al.  High-dose regimen of interleukin-2 and interferon-alpha in combination with lymphokine-activated killer cells in patients with metastatic renal cell cancer. , 1997, Journal of immunotherapy.

[132]  J. Cawley,et al.  The current status of interferon alpha in haemic malignancy. , 1990, Blood reviews.

[133]  K. Calman,et al.  Immunological Aspects of Cancer Chemotherapy , 1980 .